Actionable news
0
All posts from Actionable news
Actionable news in ARGS: ARGOS THERAPEUTICS Inc,

Argos Therapeutics to Participate in World Stem Cells and Regenerative Medicine Congress

DURHAM, N.C., May 11, 2016 (GLOBE NEWSWIRE via COMTEX) --

Argos Therapeutics, Inc. ARGS, -5.80% an immuno-oncology company focused on the development and commercialization of truly individualized immunotherapies for the treatment of cancer based on the Arcelis(R) technology platform, today announced the company will participate in the World Stem Cells and Regenerative Medicine Congress to be held May 18-20, 2016 at the Business Design Centre in London.

Fred Miesowicz, Ph.D., special advisor and former chief operating officer of Argos, will join a panel titled, "Thinking beyond efficacy - considerations for commercial success," beginning at 5pm BST on Wednesday, May 18 [th] . Dr. Miesowicz will also participate in a roundtable discussion, "Biotech updates: from head-to-toe," at 11:25am BST on Thursday, May 19 [th] .

For more information about the Congress, visit http://www.terrapinn.com/conference/world-stem-cells-regenerative-medicine-congress/index.stm.

About the Arcelis(R) Technology Platform
Arcelis(R) is a truly personalized immunotherapy technology that captures mutated and variant antigens that are specific to each patient's disease. It is designed to overcome immunosuppression by producing a durable memory T-cell response without adjuvants that may be associated with toxicity. The technology is potentially applicable to a wide range of different cancers, and is designed to overcome many of the manufacturing and commercialization challenges that have impeded other personalized cancer immunotherapies. The Arcelis(R) process uses only a small tumor or blood sample and the patient's own dendritic cells, which are optimized from cells collected by a single leukapheresis procedure...


More